umbralisib (TGR-1202)

umbralisib (TGR-1202) (CAS No.: 1532533-67-7) is a synthetic small molecule research compound in the targeted kinase inhibitor class, primarily categorized for oncology and immunology research as a selective phosphoinositide 3 kinase delta inhibitor with additional activity on casein kinase 1 epsilon, and it is broadly used to interrogate PI3K AKT mTOR associated signaling and immune regulatory networks in malignant and immune cell systems; available enzyme and cell based findings indicate potent PI3K delta pathway modulation in the nanomolar range and secondary CK1 epsilon inhibition in the micromolar range, supporting its utility for mechanistic studies of B cell receptor linked survival signaling, proliferation control, cytokine associated responses, and tumor microenvironment relevant immune modulation, including work in hematologic malignancy models and chronic lymphocytic leukemia derived cellular contexts; in biomedical discovery workflows, it is commonly applied in in vitro assays such as target engagement profiling, pathway phosphorylation analysis, viability and apoptosis measurements, and combination screening paradigms, and it may also be incorporated into in vivo preclinical pharmacology designs to assess pathway dependent antitumor biology and exposure response relationships, where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.